Vitamin B6 and Restless Legs Syndrome: Guideline Evidence
Guideline Position on Vitamin B6 as a Risk Factor
- The 2025 American Academy of Sleep Medicine (AASM) clinical practice guideline does not list excess vitamin B6 intake as a risk factor or cause of Restless Legs Syndrome (RLS). 1
- The same AASM guideline similarly omits vitamin B6 toxicity from its comprehensive review of RLS pathophysiology, emphasizing iron deficiency, dopamine dysfunction, and genetic factors as primary mechanisms. 3
Clinical Features Distinguishing RLS from B6‑Induced Neuropathy (AASM 2025)
- RLS characteristically shows a circadian pattern, with symptoms worsening in the evening/night. 2
- The relief of symptoms with movement is a key distinguishing feature of RLS. 2
- B6‑induced peripheral neuropathy typically presents with sensory loss on examination (e.g., diminished sensation) rather than the urge to move. 2
- Neuropathic symptoms from B6 toxicity do not exhibit a circadian variation, remaining constant throughout the day. 2
Therapeutic Recommendations (AASM 2025)
- The AASM guideline does not recommend vitamin B6 as a first‑line therapy for RLS; first‑line agents are gabapentinoids and iron supplementation. However, vitamin B6 (e.g., 40 mg daily) is considered a reasonable secondary option, supported by evidence from randomized controlled trials. Level of evidence: randomized trial. 1